BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32843425)

  • 1. Failure of tofacitinib to achieve an objective response in a
    Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
    Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
    Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
    Yin C; Sandoval C; Baeg GH
    Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
    Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
    Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
    Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
    Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
    Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
    Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
    J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
    Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
    [No Abstract]   [Full Text] [Related]  

  • 10. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
    Degryse S; Cools J
    J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK3
    Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
    Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
    Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
    Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
    Spinella JF; Cassart P; Richer C; Saillour V; Ouimet M; Langlois S; St-Onge P; Sontag T; Healy J; Minden MD; Sinnett D
    Oncotarget; 2016 Oct; 7(40):65485-65503. PubMed ID: 27602765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
    Springuel L; Hornakova T; Losdyck E; Lambert F; Leroy E; Constantinescu SN; Flex E; Tartaglia M; Knoops L; Renauld JC
    Blood; 2014 Dec; 124(26):3924-31. PubMed ID: 25352124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
    Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
    Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
    Uckun FM; Pitt J; Qazi S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):37-48. PubMed ID: 21070101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
    Bodaar K; Yamagata N; Barthe A; Landrigan J; Chonghaile TN; Burns M; Stevenson KE; Devidas M; Loh ML; Hunger SP; Wood B; Silverman LB; Teachey DT; Meijerink JP; Letai A; Gutierrez A
    Leukemia; 2022 Jun; 36(6):1499-1507. PubMed ID: 35411095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
    Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
    PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
    Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
    Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HiJAKing T-ALL.
    Asnafi V
    Blood; 2014 Nov; 124(20):3038-40. PubMed ID: 25395141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.